Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

KiteLock 4% EDTA Lock Solution for the Prevention of Occlusions in Children With Intestinal Failure

NCT: NCT05879835 · RECRUITING

NCT IDNCT05879835
StatusRECRUITING
Start Date2024-06-21
Completion2027-06
SponsorSterileCare Inc. (INDUSTRY)
First posted
Last updated

Brief Summary

A multi-site, randomized, 2-arm open-label trial to determine if 4% Tetrasodium (EDTA) catheter lock solution is more effective than heparin lock (standard of care) in preventing central venous catheter occlusions in children with intestinal failure (IF) on total parenteral nutrition (TPN).

Frequently Asked Questions

What is KiteLock 4% EDTA Lock Solution for the Prevention of Occlusions in Children With Intestinal Failure?

KiteLock 4% EDTA Lock Solution for the Prevention of Occlusions in Children With Intestinal Failure is a clinical trial registered under NCT05879835. Current status: RECRUITING.

What is the status of NCT05879835?

The current status of NCT05879835 (KiteLock 4% EDTA Lock Solution for the Prevention of Occlusions in Children With Intestinal Failure) is: RECRUITING.

When did KiteLock 4% EDTA Lock Solution for the Prevention of Occlusions in Children With Intestinal Failure start?

KiteLock 4% EDTA Lock Solution for the Prevention of Occlusions in Children With Intestinal Failure started on 2024-06-21.

Related Devices

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.